Visterra Inc is a United States-based biotechnology company. The Company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics. The Company’s technology is based on its Hierotope Platform, which identifies an area, or epitope, on the target protein, glycoprotein or glycan that is fundamental to its structure and function. The Company’s Hierotope Platform is able to identify the region of the protein, or epitope, which is structurally constrained, and thus prevented from mutation over time or under immunological or therapeutic pressure. Its technology for creating potent and therapeutics is powered by the Company’s computational tools and techniques, the core of which is called Atomic Interaction Network (AIN) analysis.